Apo-Semaglutide Injection : Incorrect dose display
Brand(s)
Last updated
Summary
Product
Apo-Semaglutide Injection
Issue
Health products - Product quality
What to do
Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.
Distribution
Alberta
British Columbia
Manitoba
New Brunswick
Newfoundland and Labrador
Ontario
Quebec
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot Number |
|---|---|---|---|---|---|
Apotex Inc. |
Apo-Semaglutide (4mg/pen) |
DIN 02568012 |
Solution |
1.34 mg/mL |
7000636A |
Issue
| The affected lot may display a dose of 0.25 mg or 0.5 mg in the dose window and deliver one of these doses instead of the expected 1 mg dose. |
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of Recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Apotex Inc.
150 Signet Drive,
Toronto, ON, M9L 1T9
Published by
Health Canada
Audience
General public
Healthcare
Industry
Distribution
Alberta
British Columbia
Manitoba
New Brunswick
Newfoundland and Labrador
Ontario
Quebec
Recall class
Type II
Recall date
Identification number
RA-82679
Get notified
Receive emails about new and updated recall and safety alerts.